Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3347853 | 0.91 | BTK (0.62) | BTK | |
| SCHEMBL3342314 | 0.90 | BTK (0.66) | BTK | |
| SCHEMBL23162479 | 0.90 | BTK (0.63) | BTK | |
| SCHEMBL3339682 | 0.90 | BTK (0.72) | BTK | |
| SCHEMBL3342042 | 0.90 | BTK (0.60) | BTK | |
| SCHEMBL3343369 | 0.89 | BTK (0.60) | BTK | |
| SCHEMBL3342219 | 0.89 | BTK (0.59) | BTK | |
| SCHEMBL769985 | 0.87 | BTK (0.84) | BTK | |
| SCHEMBL15875267 | 0.87 | BTK (0.69) | BTK | |
| SCHEMBL15875115 | 0.86 | BTK (0.68) | BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1863766-B1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT INC (US) | 2015-05-20 | — | — | EP | claimed |
| EP-1863766-A2 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CGI Pharmaceuticals, Inc. (US) | 2007-12-12 | — | — | EP | claimed |
| US-20060229337-A1 | Certain substituted amides, method of making, and method of use thereof | GILEAD CONNECTICUT, INC. | 2006-10-12 | — | — | US | claimed |
| WO-2006099075-A2 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CGI PHARMACEUTICALS, INC. (US) | 2006-09-21 | — | — | WO | claimed |
| US-20260014157-A1 | USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) | PHARMACYCLICS LLC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20250127781-A1 | USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) | PHARMACYCLICS, INC. | 2025-04-24 | — | — | US | disclosed |
| US-20240065971-A1 | METHODS OF TREATING ABC-DLBCL USING INHIBITORS OF BRUTONS TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2024-02-29 | — | — | US | disclosed |
| US-20230293532-A1 | USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) | PHARMACYCLICS LLC (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230248730-A1 | USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) | PHARMACYCLICS LLC (US) | 2023-08-10 | — | — | US | disclosed |
| US-11672803-B2 | Use of inhibitors of Brutons tyrosine kinase (Btk) | PHARMACYCLICS LLC (US) | 2023-06-13 | — | — | US | disclosed |
| US-20220249494-A1 | USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) | PHARMACYCLICS LLC (US) | 2022-08-11 | — | — | US | disclosed |
| US-20220175785-A1 | USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) | PHARMACYCLICS LLC (US) | 2022-06-09 | — | — | US | disclosed |
| WO-2012031004-A1 | PYRIDINONES/PYRAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2011153514-A2 | THE USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) | PHARMACYCLICS, INC. (US) | 2011-12-08 | — | — | WO | disclosed |
| US-20100160292-A1 | Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors | CGI PHARMACEUTICALS, INC (US) | 2010-06-24 | — | — | US | disclosed |
| EP-2068849-A2 | KINASE INHIBITORS, AND METHODS OF USING AND IDENTIFYING KINASE INHIBITORS | CGI Pharmaceuticals, Inc. (US) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008033858-A2 | KINASE INHIBITORS, AND METHODS OF USING AND IDENTIFYING KINASE INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| EP-1863766-A2 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CGI Pharmaceuticals, Inc. (US) | 2007-12-12 | — | — | EP | disclosed |
| US-20060229337-A1 | Certain substituted amides, method of making, and method of use thereof | GILEAD CONNECTICUT, INC. | 2006-10-12 | — | — | US | disclosed |
| WO-2006099075-A2 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CGI PHARMACEUTICALS, INC. (US) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160292-A1 | Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors | BTK, LYN, LCK | BTK 1/4885 |
| US-20260014157-A1 | USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) | BTK, BCL6B, BCL9 | BTK 1/4885 |
| US-20240065971-A1 | METHODS OF TREATING ABC-DLBCL USING INHIBITORS OF BRUTONS TYROSINE KINASE | BTK, BCL6, BCL6B | BTK 1/4885 |
| US-20220249494-A1 | USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) | BTK, LYN, SYK | BTK 1/4885 |
| US-20060229337-A1 | Certain substituted amides, method of making, and method of use thereof | BTK, SYK, MYD88 | BTK 1/4885 |
| US-20230248730-A1 | USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) | BTK, LYN, SYK | BTK 1/4885 |
| US-11672803-B2 | Use of inhibitors of Brutons tyrosine kinase (Btk) | BTK, LYN, SYK | BTK 1/4885 |
| US-20250127781-A1 | USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) | BTK, LYN, SYK | BTK 1/4885 |
| US-20230293532-A1 | USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) | BTK, LYN, SYK | BTK 1/4885 |
| US-20220175785-A1 | USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) | BTK, LYN, SYK | BTK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.